Page last updated: 2024-12-10
pramiconazole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pramiconazole: has antifungal activity; R-126638 is the (2S-cis)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3013050 |
CHEMBL ID | 175633 |
CHEBI ID | 188777 |
SCHEMBL ID | 3048310 |
MeSH ID | M0509683 |
Synonyms (30)
Synonym |
---|
azoline |
r-126638 |
pramiconazole |
1-[4-[4-[4-[[(2s,4r)-4-(2,4-difluorophenyl)-4-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-3-isopropyl-imidazolidin-2-one |
r126638 |
2-imidazolidinone, 1-[4-[4-[4-[[(2s,4r)-4-(2,4-difluorophenyl)-4-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-3-(1-methylethyl)- |
219923-85-0 |
D06630 |
pramiconazole (usan/inn) |
1-(4-(4-(4-((4-(2,4-difluorophenyl)-4-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-3-(1-methylethyl)-2-imidazolidinone |
r 126638 |
CHEMBL175633 |
1-[4-[4-[4-[[(2s,4r)-4-(2,4-difluorophenyl)-4-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-3-propan-2-ylimidazolidin-2-one |
CHEBI:188777 |
1-[4-[4-[4-[[(2s,4r)-4-(2,4-diluorophenyl)-4-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-3-propan-2-ylimidazolidin-2-one |
unii-4syh0r661f |
2-imidazolidinone, 1-(4-(4-(4-(((2s,4r)-4-(2,4-difluorophenyl)-4-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-3-(1-methylethyl)- |
4syh0r661f , |
pramiconazole [usan:inn] |
1-(4-(4-(4-(((2s,4r)-4-(2,4-difluorophenyl)-4-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-3-(1-methylethyl)imidazolidin-2-one |
pramiconazole [inn] |
1-[4-[4-[4-[[(2s,4r)-4-(2,4-difluorophenyl)-4-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-3-(1-methylethyl)imidazolidin-2-one |
pramiconazole [who-dd] |
pramiconazole [usan] |
SCHEMBL3048310 |
1-(4-(4-(4-(((2s,4r)-4-((1h-1,2,4-triazol-1-yl)methyl)-4-(2,4-difluorophenyl)-1,3-dioxolan-2-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-3-isopropylimidazolidin-2-one |
2-imidazolidinone,1-[4-[4-[4-[[(2s,4r)-4-(2,4-difluorophenyl)-4-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-3-(1-methylethyl)- |
DB06295 |
DTXSID80944594 |
AKOS040747301 |
Research Excerpts
Overview
Pramiconazole (R126638) is a novel azole with potent antifungal activity against yeasts, dermatophytes and many other fungal species. It is a well-tolerated and effective treatment for pityriasis versicolor.
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" It was concluded that there was no active metabolite present in serum samples from healthy volunteers after oral dosing of pramiconazole." | ( Absence of an active metabolite for the triazole antifungal pramiconazole. Ausma, J; Bohets, H; Borgers, M; Fothergill, A; Pennick, G; van de Velde, V, 2007) | 0.79 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
piperazines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (20)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID249329 | Minimum inhibitory concentration against Candida species (n=24) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249266 | Minimum inhibitory concentration against Microsporum species (n=38) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249273 | Minimum inhibitory concentration against Trichophyton mentagrophytes (n=20) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID246892 | Effective dose was measured in mice infected with Trichophyton mentagrophytes | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249272 | Minimum inhibitory concentration against Epidermophyton floccosum (n=12) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249264 | Minimum inhibitory concentration against Aspergillus species (n=8) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249344 | Minimum inhibitory concentration against Trichophyton mentagrophytes (n=20) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249267 | Minimum inhibitory concentration against Trichophyton rubrum (n=14) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249335 | Minimum inhibitory concentration against Trichophyton tonsurans (n=18) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249271 | Minimum inhibitory concentration against Trichophyton tonsurans (n=18) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249332 | Minimum inhibitory concentration against Trichophyton rubrum (n=14) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249269 | Minimum inhibitory concentration against Trichophyton species (n=80) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249263 | Minimum inhibitory concentration against Candida species (n=24) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID246929 | Effective dose was measured in guinea pig infected with Microsporum canis on 14th day | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID246930 | Effective dose was measured in guinea pig infected with Microsporum canis on 21st day | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID246926 | Effective dose was measured in guinea pig infected with Microsporum canis on 7th day | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249339 | Minimum inhibitory concentration against Epidermophyton floccosum (n=12) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249333 | Minimum inhibitory concentration against Trichophyton species (n=80) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249330 | Minimum inhibitory concentration against Aspergillus species (n=8) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
AID249331 | Minimum inhibitory concentration against Microsporum species (n=38) | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (85.71) | 29.6817 |
2010's | 2 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 25.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.87) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 6 (42.86%) | 5.53% |
Reviews | 1 (7.14%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (50.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |